Allogeneic stem cell transplantation in the myelodysplastic syndromes: Interim results of outcome following reduced-intensity conditioning compared with standard preparative regimens

British Journal of Haematology

Volumn 119, Issue 1, 2002, Pages 144-154

  Parker, Jane E ^a   Shafi, Tariq ^a   Pagliuca, Antonio ^a   Mijovic, Aleksandar ^a   Devereux, Stephen ^a   Potter, Mike ^b   Prentice, H Grant ^b   Garg, Mamta ^c   Yin, John A ^c   Byrne, Jenny ^d   Russell, Nigel H ^d   Mufti, Ghulam J ^a,e  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c MANCHESTER ROYAL INFIRMARY   (United Kingdom)

^d UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^e KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Allogeneic stem cell transplantation; Campath 1H; MDS; MDS AML; Reduced intensity conditioning

Indexed keywords

ALEMTUZUMAB; AMSACRINE; BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; CYTARABINE; DAUNORUBICIN; ETOPOSIDE; FLUDARABINE; IDARUBICIN; LEUKOCYTE ANTIGEN; METHOTREXATE; MITOXANTRONE; THYMOCYTE ANTIBODY; TIOGUANINE; TOPOTECAN;

ADULT; ANALGESIA; APLASIA; ARTICLE; CHIMERA; COMORBIDITY; CONTROLLED STUDY; CYTOGENETICS; FEMALE; FEVER; FLUORESCENCE IN SITU HYBRIDIZATION; GRAFT FAILURE; GRAFT VERSUS HOST REACTION; HUMAN; KARYOTYPE; MAJOR CLINICAL STUDY; MALE; MEDICAL ASSESSMENT; MORTALITY; MUCOSA INFLAMMATION; MYELODYSPLASTIC SYNDROME; NEUTROPENIA; PARENTERAL NUTRITION; PRIORITY JOURNAL; STEM CELL TRANSPLANTATION; SURVIVAL; TANDEM REPEAT; TREATMENT OUTCOME; WHOLE BODY RADIATION;

ADULT; FEMALE; GRAFT SURVIVAL; GRAFT VS HOST DISEASE; HUMANS; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; RECURRENCE; STEM CELL TRANSPLANTATION; SURVIVAL ANALYSIS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS;

EID: 18644364283     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2141.2002.03796.x     Document Type: Article

References (22)

1. van Amstel, H.K. & Reitsma, P.H. (1990) Tetranucleotide repeat polymorphism in the vWF gene. Nucleic Acids Research, 18, 4957.
2. Anderson, J.E., Appelbaum, F.R., Fisher, L.D., Schoch, G., Shulman, H., Anasetti, C., Bensinger, W.I., Bryant, E., Buckner, C.D. & Doney, K. (1993) Allogeneic bone marrow transplantation for 93 patients with myelodysplastic syndrome. Blood, 82, 677-681.
3. Anderson, J.E., Anasetti, C., Appelbaum, F.R., Schoch, G., Gooley, T.A., Hansen, J.A., Buckner, C.D., Sanders, J.E., Sullivan, K.M. & Storb, R. (1996) Unrelated donor marrow transplantation for myelodysplasia (MDS) and MDS-related acute myeloid leukaemia. British Journal of Haematology, 93, 59-67.
4. Appelbaum, F.R. & Anderson, J. (1998) Allogeneic bone marrow transplantation for myelodysplastic syndrome: outcomes analysis according to IPSS score. Leukemia, 12, 25-29s.
5. Arnold, R., de Witte, T., van Biezen, A., Hermans, J., Jacobsen, N., Runde, V., Gratwohl, A. & Apperley, J.F. (1998) Unrelated bone marrow transplantation in patients with myelodysplastic syndromes and secondary acute myeloid leukemia: an EBMT survey. European Blood and Marrow Transplantation Group. Bone Marrow Transplantation, 21, 1213-1216.
6. Aul, C., Runde, V. & Gatterman, N. (1993) All-trans retinoic acid in patients with myelodysplastic syndromes: results of a pilot study. Blood, 82, 2967-2974.
7. De Witte, T., Suciu, S., Peetermans, M., Fenaux, P., Strijckmans, P., Hayat, M., Jaksic, B., Selleslag, D., Zittoun, R., Dardenne, M., Solbu, G., Zwierzina, H. & Muus, P. (1995) Intensive chemotherapy for poor prognosis myelodysplasia (MDS) and secondary acute myeloid leukemia (sAML) following MDS of more than 6 months duration. A pilot study by the Leukemia Cooperative Group of the European Organisation for Research and Treatment in Cancer (EORTC-LCG). Leukemia, 9, 1805-1811.
8. Giralt, S., Estey, E., Albitar, M., van Besien, K., Rondon, G., Anderlini, P., O'Brien, S., Khouri, I., Gajewski, J., Mehra, R., Claxton, D., Andersson, B., Beran, M., Przepiorka, D., Koller, C., Kornblau, S., Korbling, M., Keating, M., Kantarjian, H. & Champlin, R. (1997) Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy. Blood, 89, 4531-4536.
9. Glucksberg, H., Storb, R., Fefer, A., Buckner, C.D., Neiman, P.E., Clift, R.A., Lerner, K.G. & Thomas, E.D. (1974) Clinical manifestations of graft versus host disease in human recipients of marrow from HLA matched sibling donors. Transplantation, 18, 295-304.
10. Goodman, E.R., Fiedor, P.S., Fein, S., Sung, R.S., Athan, E. & Hardy, M.A. (1995) Fludarabine phosphate and 2-chlorodeoxy-adenosine: Immunosuppressive DNA synthesis inhibitors with potential application in islet allo-xenotransplantation. Transplant Procedures, 27, 3293-3294.
11. Greenberg, P., Taylor, K., Larson, R., Koeffler, P., Negrin, R., Saba, H., Ganser, A., Jakubowski, A., Gabrilove, J., Mufti, G., Cruz, J., Hammond, W., Broudy, V., Langley, G.R., Keating, A., Vardiman, J., Lamborn, K. & Brown, S. (1993) Phase III randomized multicenter trial of G-CSF vs observation for myelodysplastic syndromes (MDS). Blood, 82, 196a.
12. Greenberg, P., Cox, C., LeBeau, M.M., Fenaux, P., Morel, P., Sanz, G., Sanz, M., Vallespi, T., Hamblin, T., Oscier, D., Ohyashiki, K., Toyama, K., Aul, C., Mufti, G. & Bennett, J. (1997) International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood, 89, 2079-2088.
13. Hale, G., Bright, S., Chumbley, G., Hoang, T., Metcalf, D., Munro, A.J. & Waldmann, H. (1983) Removal of T cells from bone marrow for transplantation: a monoclonal antilymphocyte antibody that fixes human complement. Blood, 62, 873-882.
14. Hale, G., Zhang, M.J., Bunjes, D., Prentice, H.G., Spence, D., Horowitz, M.M., Barrett, A.J. & Waldmann, H. (1998) Improving the outcome of bone marrow transplantation by using CD52 monoclonal antibodies to prevent graft-versus-host disease and graft rejection. Blood, 92, 4581-4590.
15. Keating, S., Suciu, S., de Witte, T., Mandelli, F., Willemze, R., Resegotti, L., Broccia, G., Thaler, J., Labar, B., Damasio, E., Bizzi, B., Rotoli, B., Vekhoff, A., Muus, P., Petti, M.C., Dardenne, M., Solbu, G., Vegna, M.L. & Zittoun, R.A. for the European Organization for Research and Treatment of Cancer (EORTC) and the Gruppo Italiano Malattie Ematologische Maligne dell'Adulto (GIMEMA) Leukemia Co-operative Groups. (1996) Prognostic factors of patients with acute myeloid leukemia (AML) allografted in first complete remission: An analysis of the EORTC-GIMEMA AML 8A trial. Bone Marrow Transplantation, 17, 993-1001.
16. Morel, P., Declercq, C., Hebbar, M., Bauters, F. & Fenaux, P. (1996) Prognostic factors in myelodysplastic syndromes: critical analysis of the impact of age and gender and the failure to identify a very-low-risk group using standard mortality ratio techniques. British Journal of Haematology, 94, 116-119.
17. Mufti, G.J. & Galton, D.A. (1986) Myelodysplastic syndromes: natural history and features of prognostic importance. Clinical Haematology, 15, 953-971.
18. Nevill, T.J., Fung, H.C., Shepherd, J.D., Nevill, T.J., Fung, H.C., Shepherd, J.D., Horsman, D.E., Nantel, S.H., Klingemann, H.G., Forrest, D.L., Toze, C.L., Sutherland, H.J., Hogge, D.E., Naiman, S.C., Le, A., Brockington, D.A. & Barnett, M.J. (1998) Cytogenetic abnormalities in primary myelodysplastic syndrome are highly predictive of outcome after allogeneic bone marrow transplantation. Blood, 92, 1910-1917.
19. Schulman, H.M., Sullivan, K.M., Weiden, P.L., McDonald, G.B., Striker, G.E., Sale, G.E., Hackman, R., Tsoi, M.S., Storb, R. & Thomas, E.D. (1980) Chronic graft-versus-host disease syndrome in man. A long term clinical pathologic study of 20 Seattle patients. American Journal of Medicine, 69, 204-217.
20. Slavin, S., Nagler, A., Naparstek, E., Kapelushnik, Y., Aker, M., Cividalli, G., Varadi, G., Kirschbaum, M., Ackerstein, A., Samuel, S., Amar, A., Brautbar, C., Ben-Tal, O., Eldor, A. & Or, R. (1998) Non- myeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood, 91, 756-763.
21. Sutton, L., Chastang, C., Ribaud, P., Jouet, J.P., Kuentz, M., Attal, M., Reiffers, J., Tigaud, J.M., Rio, B., Dauriac, C., Legros, M., Dreyfus, F., Lioure, B., Troussard, X., Milpied, N., Witz, F., Oriol, P., Cahn, J.Y., Michallet, M., Gluckman, E., Ifrah, N., Pico, J.L., Vilmer, E. & Leblond, V. (1996) Factors influencing outcome in de novo myelodysplastic syndromes treated by allogeneic bone marrow transplantation: a long-term study of 71 patients Societe Francaise de Greffe de Moelle. Blood, 88, 358-365.
22. Wijermans, P., Lübbert, M., Verhoef, G., Bosly, A., Ravoet, C., Andre, M. & Ferrant, A. (2000) Low-Dose 5-Aza-2′-Deoxycytidine, a DNA Hypomethylating Agent, for the Treatment of High-Risk Myelodysplastic Syndrome: a Multicenter Phase II Study in Elderly Patients. Journal of Clinical Oncology, 18, 956-962.